How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery

被引:9
作者
Bhagwat, Amala [1 ]
Deshpande, Aditi [1 ]
Parish, Tanya [1 ]
机构
[1] Seattle Childrens Res Inst, Ctr Global Infect Dis Res, Seattle, WA 98101 USA
基金
美国国家卫生研究院;
关键词
Mycobacterium tuberculosis; antibiotic resistance; drug discovery; antibiotic tolerance; antibacterial; FLUOROQUINOLONE-RESISTANT; ANTITUBERCULOSIS DRUGS; KANAMYCIN RESISTANCE; BETA-LACTAMS; DNA GYRASE; MUTATIONS; INHA; INHIBITORS; TARGET; REDUCTASE;
D O I
10.3389/fcimb.2022.974101
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug resistance is an increasing problem for the treatment of tuberculosis. The prevalence of clinical isolates with pre-existing resistance needs to be considered in any drug discovery program. Non-specific mechanisms of resistance such as increased efflux or decreased permeability need to be considered both in developing individual drug candidates and when designing novel regimens. We review a number of different approaches to develop new analogs and drug combinations or improve efficacy of existing drugs that may overcome or delay the appearance of clinical resistance. We also discuss the need to fully characterize mechanisms of resistance and cross- resistance to existing drugs to ensure that novel drugs will be clinically effective.
引用
收藏
页数:8
相关论文
共 86 条
[1]   Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? [J].
Alfarisi, Omamah ;
Alghamdi, Wael A. ;
Al-Shaer, Mohammad H. ;
Dooley, Kelly E. ;
Peloquin, Charles A. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) :1027-1036
[2]   Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis [J].
Almeida, Deepak ;
Ioerger, Thomas ;
Tyagi, Sandeep ;
Li, Si-Yang ;
Mdluli, Khisimuzi ;
Andries, Koen ;
Grosset, Jacques ;
Sacchettini, Jim ;
Nuermberger, Eric .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) :4590-4599
[3]   Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline [J].
Andries, Koen ;
Villellas, Cristina ;
Coeck, Nele ;
Thys, Kim ;
Gevers, Tom ;
Vranckx, Luc ;
Lounis, Nacer ;
de Jong, Bouke C. ;
Koul, Anil .
PLOS ONE, 2014, 9 (07)
[4]   Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives [J].
Armstrong, Tom ;
Lamont, Malcolm ;
Lanne, Alice ;
Alderwick, Luke J. ;
Thomas, Neil R. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (22)
[5]   Mycobacterium tuberculosis DNA gyrase:: Interaction with quinolones and correlation with antimycobacterial drug activity [J].
Aubry, A ;
Pan, XS ;
Fisher, LM ;
Jarlier, V ;
Cambau, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1281-1288
[6]   Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium tuberculosis Isolates: A Systematic Review [J].
Avalos, Elisea ;
Catanzaro, Donald ;
Catanzaro, Antonino ;
Ganiats, Theodore ;
Brodine, Stephanie ;
Alcaraz, John ;
Rodwell, Timothy .
PLOS ONE, 2015, 10 (03)
[7]   INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS [J].
BANERJEE, A ;
DUBNAU, E ;
QUEMARD, A ;
BALASUBRAMANIAN, V ;
UM, KS ;
WILSON, T ;
COLLINS, D ;
DELISLE, G ;
JACOBS, WR .
SCIENCE, 1994, 263 (5144) :227-230
[8]   Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones [J].
Basarab, Gregory S. ;
Ghorpade, Sandeep ;
Gibhard, Liezl ;
Mueller, Rudolf ;
Njoroge, Mathew ;
Peton, Nashied ;
Govender, Preshendren ;
Massoudi, Lisa M. ;
Robertson, Gregory Thomas ;
Lenaerts, Anne J. ;
Boshoff, Helena Ingrid ;
Joerss, Douglas ;
Parish, Tanya ;
Durand-Reville, Thomas F. ;
Perros, Manos ;
Singh, Vinayak ;
Chibale, Kelly .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (04)
[9]   Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase [J].
Carta, Antonio ;
Bua, Alessandra ;
Corona, Paola ;
Piras, Sandra ;
Briguglio, Irene ;
Molicotti, Paola ;
Zanetti, Stefania ;
Laurini, Erik ;
Aulic, Suzana ;
Fermeglia, Maurizio ;
Pricl, Sabrina .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 161 :399-415
[10]   In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations [J].
Cavusoglu, C ;
Karaca-Derici, Y ;
Bilgic, A .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (07) :662-665